

# Inge M Van Oort

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6224778/publications.pdf>

Version: 2024-02-01

170  
papers

8,544  
citations

70961

41  
h-index

46693

89  
g-index

172  
all docs

172  
docs citations

172  
times ranked

10997  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging. <i>Radiology</i> , 2011, 261, 46-66.	3.6	618
2	DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer. <i>European Urology</i> , 2003, 44, 8-16.	0.9	603
3	Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer. <i>Radiology</i> , 2011, 259, 453-461.	3.6	537
4	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. <i>European Urology</i> , 2019, 75, 570-578.	0.9	521
5	Magnetic Resonance Imaging Guided Prostate Biopsy in Men With Repeat Negative Biopsies and Increased Prostate Specific Antigen. <i>Journal of Urology</i> , 2010, 183, 520-528.	0.2	344
6	Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2009, 41, 1122-1126.	9.4	313
7	Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer. <i>European Urology</i> , 2014, 65, 534-542.	0.9	306
8	Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. <i>European Urology</i> , 2016, 70, 740-748.	0.9	292
9	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
10	Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging-Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort. <i>European Urology</i> , 2012, 61, 177-184.	0.9	277
11	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011, 43, 1098-1103.	9.4	251
12	Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3061-3070.	3.2	193
13	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , 2012, 44, 1326-1329.	9.4	178
14	The Predictive Value of Endorectal 3 Tesla Multiparametric Magnetic Resonance Imaging for Extraprostatic Extension in Patients with Low, Intermediate and High Risk Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 1728-1734.	0.2	177
15	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1250-1264.	5.1	159
16	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. <i>Science Translational Medicine</i> , 2010, 2, 62ra92.	5.8	140
17	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. <i>Nature Communications</i> , 2019, 10, 5251.	5.8	130
18	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. <i>Cancer</i> , 2014, 120, 968-975.	2.0	121

#	ARTICLE	IF	CITATIONS
19	High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. <i>European Urology</i> , 2019, 76, 574-581.	0.9	114
20	Thirty-Two-Channel Coil 3T Magnetic Resonance-Guided Biopsies of Prostate Tumor Suspicious Regions Identified on Multimodality 3T Magnetic Resonance Imaging: Technique and Feasibility. <i>Investigative Radiology</i> , 2008, 43, 686-694.	3.5	104
21	Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 12-19.	2.0	102
22	Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes. <i>Journal of Urology</i> , 2014, 191, 1132-1138.	0.2	95
23	Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. <i>European Journal of Cancer</i> , 2014, 50, 1090-1099.	1.3	88
24	Value of 3-T Multiparametric Magnetic Resonance Imaging and Magnetic Resonance-Guided Biopsy for Early Risk Restratification in Active Surveillance of Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2014, 49, 165-172.	3.5	83
25	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1369-1380.	1.6	74
26	Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 4510-4515.	0.8	72
27	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
28	Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score $\geq 3 + 3 = 6$ Upon Schematic TRUS-Guided Biopsy. <i>Investigative Radiology</i> , 2012, 47, 153-158.	3.5	65
29	Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2013, 48, 152-157.	3.5	63
30	Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e1-71.e9.	0.8	62
31	Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. <i>BJU International</i> , 2013, 111, 564-573.	1.3	61
32	Fear of cancer recurrence in prostate cancer survivors. <i>Acta Oncologica</i> , 2016, 55, 821-827.	0.8	61
33	A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. <i>Prostate</i> , 2017, 77, 1401-1407.	1.2	61
34	Feasibility of 3T Dynamic Contrast-Enhanced Magnetic Resonance-Guided Biopsy in Localizing Local Recurrence of Prostate Cancer After External Beam Radiation Therapy. <i>Investigative Radiology</i> , 2010, 45, 121-125.	3.5	56
35	Quality of life after prostate cancer treatments in patients comparable at baseline. <i>British Journal of Cancer</i> , 2013, 108, 1784-1789.	2.9	56
36	The prognostic value of E-cadherin and the cadherin-associated molecules $\beta$ -catenin and p120 <sup>cas</sup> in prostate cancer specific survival: A long-term follow-up study. <i>Prostate</i> , 2007, 67, 1432-1438.	1.2	54

#	ARTICLE	IF	CITATIONS
37	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	3.2	53
38	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
39	The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy. <i>Histopathology</i> , 2010, 56, 464-471.	1.6	49
40	Does the Tertiary Gleason Pattern Influence the PSA Progression-Free Interval after Retropubic Radical Prostatectomy for Organ-Confined Prostate Cancer?. <i>European Urology</i> , 2005, 48, 572-576.	0.9	47
41	Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 483-492.	1.4	47
42	Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients With Lymph Node Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 712-718.	0.4	45
43	Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics – a decision analytical model. <i>BJU International</i> , 2017, 120, 659-665.	1.3	45
44	Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 336-342.	1.2	41
45	Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 122-129.	1.1	41
46	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 136, 16-24.	1.3	41
47	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1110-1119.	2.0	40
48	Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial. <i>Health Expectations</i> , 2016, 19, 459-470.	1.1	39
49	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 423-430.	2.0	37
50	CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. <i>International Journal of Cancer</i> , 2015, 136, E760-72.	2.3	34
51	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e7-729.e16.	0.8	34
52	Fear of cancer recurrence: a significant concern among partners of prostate cancer survivors. <i>Psycho-Oncology</i> , 2017, 26, 2079-2085.	1.0	33
53	Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 884.	1.1	32
54	Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. <i>European Journal of Cancer</i> , 2010, 46, 3294-3299.	1.3	31

#	ARTICLE	IF	CITATIONS
55	A Quantitative Analysis Investigating the Prevalence of “Manels” in Major Urology Meetings. <i>European Urology</i> , 2021, 80, 442-449.	0.9	31
56	Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. <i>European Urology Oncology</i> , 2020, 3, 231-238.	2.6	30
57	The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care—A Systematic Review. <i>Cancers</i> , 2022, 14, 1059.	1.7	30
58	Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. <i>BJU International</i> , 2015, 115, 571-579.	1.3	29
59	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <i>Prostate</i> , 2014, 74, 1222-1230.	1.2	28
60	Novel use of Twitter to disseminate and evaluate adherence to clinical guidelines by the European Association of Urology. <i>BJU International</i> , 2017, 119, 820-822.	1.3	28
61	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 385-395.	2.3	28
62	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e223-e231.	0.9	27
63	Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. <i>World Journal of Urology</i> , 2008, 26, 237-241.	1.2	26
64	Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 238-250.e1.	0.9	26
65	Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. <i>International Journal of Molecular Sciences</i> , 2013, 14, 11347-11355.	1.8	25
66	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	1.5	25
67	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. <i>Future Oncology</i> , 2020, 16, 1371-1384.	1.1	25
68	The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system. <i>BJU International</i> , 2008, 102, 438-441.	1.3	23
69	Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. <i>BJU International</i> , 2009, 104, 321-325.	1.3	23
70	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019, 5, 407-415.	1.6	23
71	Nationwide treatment patterns and survival of older patients with prostate cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 252-258.	0.5	19
72	Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 735.e17-735.e25.	0.8	19

#	ARTICLE	IF	CITATIONS
73	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	2.0	19
74	Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy. <i>Histopathology</i> , 2011, 59, 692-702.	1.6	18
75	Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy. <i>World Journal of Urology</i> , 2012, 30, 105-110.	1.2	18
76	223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases. <i>Clinical Nuclear Medicine</i> , 2018, 43, 9-16.	0.7	18
77	Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 79-87.	0.9	18
78	A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines. <i>European Urology Focus</i> , 2021, 7, 1195-1204.	1.6	18
79	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 714-729.	1.5	18
80	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. <i>European Urology Oncology</i> , 2020, 3, 455-463.	2.6	17
81	A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant". <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 509-513.	0.8	15
82	Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3325-3334.	3.3	15
83	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) " updated interim analysis (IA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5566-5566.	0.8	15
84	Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. <i>Therapeutic Advances in Urology</i> , 2014, 6, 245-252.	0.9	14
85	The oncologic role of local treatment in primary metastatic prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 755-761.	1.2	14
86	Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e1-265.e7.	0.8	14
87	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. <i>Prostate</i> , 2016, 76, 32-40.	1.2	13
88	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. <i>Trials</i> , 2021, 22, 768.	0.7	13
89	Known susceptibility SNPs for sporadic prostate cancer show a similar association with "hereditary" prostate cancer. <i>Prostate</i> , 2015, 75, 474-483.	1.2	12
90	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 222-229.	1.0	11

#	ARTICLE	IF	CITATIONS
91	68Ga-PSMAâ€“Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1607-1614.	2.8	11
92	Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 344-344.	0.8	11
93	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. <i>Oncology</i> , 2016, 91, 267-273.	0.9	10
94	PREDICT: model for prediction of survival in localized prostate cancer. <i>World Journal of Urology</i> , 2016, 34, 789-795.	1.2	10
95	A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1179-1185.	1.1	9
96	Implementation of a decision aid for localized prostate cancer in routine care: A successful implementation strategy. <i>Health Informatics Journal</i> , 2020, 26, 1194-1207.	1.1	9
97	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRM) and metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 93-93.	0.8	9
98	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castrationâ€“resistant prostate cancer undergoing firstâ€“line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021, 15, 2453-2465.	2.1	9
99	The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited. <i>Prostate</i> , 2016, 76, 897-904.	1.2	8
100	68Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 147-154.	0.9	8
101	The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 871-879.	2.0	8
102	Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 55, e6-e8.	0.6	7
103	The Combination of Enzalutamide and Opioids: A Painful Pitfall?. <i>European Urology</i> , 2019, 75, 351-352.	0.9	7
104	Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative. <i>Journal of Cancer Education</i> , 2020, 35, 1141-1148.	0.6	7
105	Urologistsâ€™ and GPsâ€™ knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands. <i>Familial Cancer</i> , 2012, 11, 195-200.	0.9	6
106	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Oncology</i> , 2021, 4, 618-627.	2.6	6
107	Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study. <i>European Urology Focus</i> , 2021, 7, 332-339.	1.6	6
108	Adjustment disorder in cancer patients after treatment: prevalence and acceptance of psychological treatment. <i>Supportive Care in Cancer</i> , 2022, 30, 1797-1806.	1.0	6

#	ARTICLE	IF	CITATIONS
109	Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1374-1385.	1.5	6
110	Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e946-e956.	0.9	5
111	The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 753-760.	1.1	5
112	Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer. <i>BJU International</i> , 2022, 129, 480-490.	1.3	5
113	The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1170-1178.	1.1	5
114	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 248-248.	0.8	5
115	Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 771956.	1.3	5
116	Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling. <i>Archivos Espanoles De Urologia</i> , 2015, 68, 296-306.	0.1	5
117	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 907-916.	2.9	5
118	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 6279.	1.7	5
119	Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 142-150.	2.0	5
120	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e233-e253.	0.9	4
121	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	1.3	4
122	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 3756.	1.7	4
123	Optimizing psychosocial support in prostate cancer patients during active surveillance. <i>International Journal of Urological Nursing</i> , 2020, 14, 115-123.	0.1	4
124	High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. <i>Journal of Palliative Medicine</i> , 2021, 24, 1789-1797.	0.6	4
125	Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. <i>Eur Urol</i> 2021;80:442-9. <i>European Urology</i> , 2021, 80, e101.	0.9	4
126	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	0.9	4



#	ARTICLE	IF	CITATIONS
127	Self-reported acne is not associated with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 941-945.	0.8	3
128	Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 337-343.	2.0	3
129	Histopathological re-evaluations of biopsies in prostate cancer: a nationwide observational study. <i>Scandinavian Journal of Urology</i> , 2020, 54, 463-469.	0.6	3
130	Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.. <i>Journal of Clinical Oncology</i> , 2020, 38, 121-121.	0.8	3
131	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52.	0.9	3
132	Dissemination of the European Association of Urology Guidelines Through Social Media: Strategy, Results, and Future Developments. <i>European Urology Focus</i> , 2022, 8, 1541-1544.	1.6	3
133	Editorâ€™ summary: A paradigm shift in castration-resistant prostate cancer management. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 601-603.	2.0	3
134	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. <i>Oncolmmunology</i> , 2022, 11, .	2.1	3
135	VALUE OF 3 TESLA MULTI-MODALITY DIRECTED MR GUIDED BIOPSY TO DETECT PROSTATE CANCER IN PATIENTS AFTER AT LEAST TWO PREVIOUS NEGATIVE BIOPSIES AND ELEVATED PSA. <i>Journal of Urology</i> , 2009, 181, 706.	0.2	2
136	2104 PROSPECTIVE MULTICENTER EVALUATION OF PCA3 AND TMPRSS2-ERG GENE FUSIONS AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.2	2
137	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5036-5036.	0.8	2
138	Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 219-219.	0.8	2
139	An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	0.7	2
140	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5051-5051.	0.8	2
141	Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 133-141.	2.0	2
142	Prognostic Factors in Radical Prostatectomy Specimens: What Do We Need to Know from Pathologists?. <i>European Urology Supplements</i> , 2008, 7, 715-722.	0.1	1
143	THE CORRELATION BETWEEN THE LENGTH OF POSITIVE SURGICAL MARGINS AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2008, 179, 196-196.	0.2	1
144	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	1.6	1

#	ARTICLE	IF	CITATIONS
145	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. Journal of Clinical Oncology, 2021, 39, 5047-5047.	0.8	1
146	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology, 2012, 30, 172-172.	0.8	1
147	Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. Journal of Clinical Oncology, 2013, 31, 5055-5055.	0.8	1
148	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. Journal of Clinical Oncology, 2016, 34, 330-330.	0.8	1
149	Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. Journal of Clinical Oncology, 2014, 32, 242-242.	0.8	1
150	Elevated HOXC6/DLX1 mRNA biomarker levels in urine to help select patients at increased risk for high-grade prostate cancer detection upon prostate biopsy.. Journal of Clinical Oncology, 2016, 34, 31-31.	0.8	1
151	POSITIVE MARGINS AFTER RADICAL PROSTATECTOMY, DOES NUMBER OF MARGINS AND SITE MATTER?. Journal of Urology, 2008, 179, 197-198.	0.2	0
152	1907 CORRELATION OF PCA3 AND MRI WITH BIOPSY OUTCOME. Journal of Urology, 2011, 185, .	0.2	0
153	PD14-10 CURRENT TRENDS IN MANAGEMENT OF HIGH-RISK PROSTATE CANCER IN EUROPE: RESULTS OF A WEB-BASED SURVEY BY THE PROSTATE CANCER WORKING GROUP OF THE YOUNG ACADEMIC UROLOGISTS WORKING PARTY OF THE EUROPEAN ASSOCIATION OF UROLOGY. Journal of Urology, 2014, 191, .	0.2	0
154	MP02-02 MULTICENTER VALIDATION STUDY OF A MOLECULAR URINE TEST TO PREDICT HIGH-GRADE PROSTATE CANCER.. Journal of Urology, 2016, 195, .	0.2	0
155	MP63-14 THE IMPACT OF A MINIMUM CYSTECTOMY VOLUME POLICY ON THE CENTRALIZATION AND QUALITY OF BLADDER CANCER CARE IN THE NETHERLANDS. Journal of Urology, 2016, 195, .	0.2	0
156	PD47-05 ELDERLY PROSTATE CANCER PATIENTS HAVE A WORSE PROGNOSIS THAN YOUNGER PATIENTS: A POPULATION-BASED STUDY IN THE NETHERLANDS.. Journal of Urology, 2017, 197, .	0.2	0
157	MP33-17 POTENTIAL ROLE OF A NOVEL URINARY BIOMARKER-BASED RISK SCORE TO SELECT PATIENTS FOR MULTIPARAMETRIC MRI FOR PROSTATE CANCER DETECTION.. Journal of Urology, 2017, 197, .	0.2	0
158	Abstract CT027: TALAPRO-1 final data: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin and zygosity. , 2021, , .		0
159	468: Prognostic Significance of Number of Tumors in T2C Prostate Cancer. Journal of Urology, 2007, 177, 157-157.	0.2	0
160	331: The 2002 TNM Subclassification of Unilateral PT2 Prostate Cancer is not Relevant. Journal of Urology, 2007, 177, 112-112.	0.2	0
161	1877: Are Small-Volume Prostate Cancers Insignificant?. Journal of Urology, 2007, 177, 623-624.	0.2	0
162	1156: Maximal Tumor Diameter is not a Prognostic Factor for Biochemical Recurrence in Patients with Prostate Cancer. Journal of Urology, 2007, 177, 381-382.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Value of multimodality MRI and MR-guided biopsy at inclusion in an active surveillance protocol for prostate cancer.. Journal of Clinical Oncology, 2012, 30, 105-105.	0.8	0
164	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology, 2012, 30, e15112-e15112.	0.8	0
165	Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.. Journal of Clinical Oncology, 2014, 32, 109-109.	0.8	0
166	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. Journal of Clinical Oncology, 2016, 34, 329-329.	0.8	0
167	Does a food intervention makes abiraterone treatment affordable?. Journal of Clinical Oncology, 2019, 37, e16523-e16523.	0.8	0
168	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
169	First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. Journal of Clinical Oncology, 2022, 40, 40-40.	0.8	0
170	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. Drugs - Real World Outcomes, 2022, , 1.	0.7	0